The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment

Niels T Foged, Anja Brügmann, Jan T Jørgensen

Research output: Contribution to journalJournal articleResearchpeer-review

8 Citations (Scopus)

Abstract

Testing for amplification of the human EGF receptor 2 (HER2) gene by in situ hybridization is a central principle for the identification of breast cancer patients likely to respond to treatments directed toward HER2. However, its application in clinical routine has been somewhat restricted by the typical use of a visualization system based on fluorescence (FISH), which requires skilled, work-intensive, high-magnification quantitative microscopy. The US FDA has recently approved the HER2 CISH pharmDx™ Kit, which is characterized by employing a chromogenic visualization system that allows quantification of the HER2 gene and centromere 17 reference signals by relatively low-magnification brightfield microscopy. It is indicated as an aid in the assessment of patients for whom Herceptin(®) (trastuzumab) treatment is being considered.

Original languageEnglish
JournalExpert Review of Molecular Diagnostics
Volume13
Issue number3
Pages (from-to)233-42
Number of pages10
ISSN1473-7159
DOIs
Publication statusPublished - Apr 2013

Keywords

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Chromogenic Compounds
  • Diagnostic Test Approval
  • Female
  • Humans
  • In Situ Hybridization
  • Receptor, erbB-2

Fingerprint

Dive into the research topics of 'The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment'. Together they form a unique fingerprint.

Cite this